U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06850571) titled 'Aflibercept and Bevacizumab for Diabetic Maculopathies' on Feb. 15.
Brief Summary: The goal of this clinical trial is to to evaluate the clinical outcomes following treatment with bevacizumab versus aflibercept. These outcomes include:
* Functional changes: The visual outcomes achieved by testing visual acuity
* Anatomical changes: macular thickness and edema by optical coherence tomography (OCT).
Study Start Date: Feb. 20
Study Type: INTERVENTIONAL
Condition:
Diabetic Maculopathy
Intervention:
DRUG: Bevacizumab Injection [Avastin]
1.25 mg intravitreal injection given once monthly for three consecutive months.
DRUG: Aflibe...